<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909011</url>
  </required_header>
  <id_info>
    <org_study_id>#199-11</org_study_id>
    <nct_id>NCT01909011</nct_id>
  </id_info>
  <brief_title>A Single Blind Study of Cranial Electrical Stimulation in Bipolar II Disorder</brief_title>
  <official_title>A Single Blind, Randomized, Sham Controlled Study of Cranial Electrical Stimulation in Bipolar II Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the antidepressant effects of Cranial Electrotherapy&#xD;
      Stimulation (CES) in the depressed phase of bipolar II disorder.; to examine the safety of&#xD;
      daily CES in bipolar II patients; and to examine the effects of 20 minutes of daily CES on&#xD;
      EEG reading.&#xD;
&#xD;
      The investigators hypothesize:&#xD;
&#xD;
        1. The CES will reduce symptom severity more than sham (placebo) CES.&#xD;
&#xD;
        2. That CES administered for 20 minutes daily for four weeks is safe and well tolerated&#xD;
           when treating bipolar II patients.&#xD;
&#xD;
        3. That CES will shift the alpha and beta power fractions of EEG downward, and that this&#xD;
           shift correlates with a decrease in level of anxiety and depression&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I. ABSTRACT&#xD;
&#xD;
      Cranial electrical stimulation (CES) is a non-invasive brain stimulation technology that uses&#xD;
      a small alternating current (1-2mA) applied to the scalp to affect brain function. The&#xD;
      strength of the current is similar to that used by transcranial direct current stimulation&#xD;
      (tDCS); the only difference is that in the case of CES the current is alternating. CES has&#xD;
      been FDA sanctioned for the treatment of depression, anxiety and insomnia since 1978. CES was&#xD;
      never subjected to the level of regulatory review now required for new technologies because&#xD;
      it was &quot;grandfather-ed&quot; based on a device that predated the current FDA regulations. As a&#xD;
      consequence, although hundreds of thousands of people have been treated with CES since its&#xD;
      development in the 1950's, claims for its effectiveness have been largely anecdotal and the&#xD;
      studies have been hampered by poor study design and inadequate blinding. It is important to&#xD;
      study under well-controlled conditions whether this product, already in widespread use, is&#xD;
      truly effective. This study will examine the efficacy of CES in treating the depressive phase&#xD;
      of bipolar II disorder using a rigorous controlled design. It will be the first study of the&#xD;
      use of CES in bipolar II disorder, and the first well controlled study of the antidepressant&#xD;
      effects of CES. Because CES is already clinically available and large numbers of patients&#xD;
      have received it (usually as an at-home, self treatment), it is important to conduct a&#xD;
      randomized controlled trial rather than to merely replicate the anecdotal reports that&#xD;
      already exist in the literature.&#xD;
&#xD;
      II. RESEARCH PLAN&#xD;
&#xD;
        1. Background and Rationale&#xD;
&#xD;
           Regulatory Status of CES&#xD;
&#xD;
           CES is currently FDA sanctioned and may be marketed for the treatment of depression,&#xD;
           anxiety and insomnia. The Fisher-Wallace Cranial Stimulator (model SBL500-B), which&#xD;
           became FDA sanctioned for the treatment of anxiety, insomnia, and depression in 1990&#xD;
           (510K approval), uses 0.5-2 mA (milliampere) of alternating currents in three&#xD;
           frequencies (15Hz, 500 Hz, 15,000Hz) and is the same device as the Liss Cranial&#xD;
           Stimulator (model SBL201-M), a class III device, which has been marketed since the&#xD;
           1970's for treatment of depression, anxiety and insomnia.&#xD;
&#xD;
           State of the Evidence on the Clinical Efficacy of CES&#xD;
&#xD;
           Although CES has been in wide usage both in Europe and the United States for more than&#xD;
           50 years; there are few well controlled studies published which demonstrate its&#xD;
           efficacy. Its mechanism of action is unknown, though recent EEG studies suggest an&#xD;
           effect on brain oscillations (Marshall et al., 2006. Schroeder et al., 2001). It appears&#xD;
           to be benign, and no adverse events have been reported in the literature except for mild&#xD;
           headache and tingling under the electrodes.&#xD;
&#xD;
           The results of a 1992 meta-analysis by the Harvard School of Public Health of the&#xD;
           effectiveness of CES concluded that published studies on CES are hampered by poor study&#xD;
           design and inadequate blinding.&#xD;
&#xD;
           Using as their gold standard a randomized controlled trial comparing CES with sham in a&#xD;
           double-blind manner, they rejected studies from the former Soviet Union, which were only&#xD;
           uncontrolled. Searching human studies in English they found 18 randomized controlled&#xD;
           trials of CES vs. sham, using a variety of CES devices to treat depression, anxiety,&#xD;
           drug addiction, insomnia, headache and pain. In this analysis, they did not analyze&#xD;
           differences in signal parameters or treatment regimens.&#xD;
&#xD;
           Purpose of the Present Study&#xD;
&#xD;
           This is a single-blind, randomized, sham controlled study to evaluate the efficacy of&#xD;
           CES in treating the depressive phase in patients with bipolar II disorder. This will be&#xD;
           the first well controlled study of the role of CES in treating depression as well as the&#xD;
           first well controlled study of the role of CES in treating bipolar II disorder.&#xD;
&#xD;
           We decided to focus on depression in the context of bipolar II disorder because there is&#xD;
           a need to increase the number of effective treatments for the depressive phase of&#xD;
           bipolar II disorder, and to identify effective antidepressants that do not promote a&#xD;
           switch to mania. To this end, we will assess risk of hypomania or mania using&#xD;
           standardized scales. Of note, there have been no reported cases of hypomania or mania&#xD;
           with CES. Furthermore, we wanted to increase sample homogeneity by limiting the study to&#xD;
           bipolar II patients, and have therefore excluded unipolar depressive disorder as well as&#xD;
           bipolar I disorder.&#xD;
&#xD;
           We will recruit 20 bipolar II patients aged 18-85 who are currently in a depressive&#xD;
           phase of their illness (mixed and manic episodes will be excluded). They will be&#xD;
           randomly assigned to two groups: a placebo group and an active group, for the first two&#xD;
           weeks of the study. The CES device which we will use will be the Fisher-Wallace Cranial&#xD;
           Stimulator, which uses 1mA (milliampere) of alternating current in three frequencies&#xD;
           (5Hz, 500Hz, and 15,000Hz). In this study, patients will receive CES for 20 minutes a&#xD;
           day, five days a week. Patients will be able to remain on their medications to avoid the&#xD;
           risk to subjects by withdrawing them from medication, but the dosages must be kept&#xD;
           stable for at least two weeks prior to entering the study and for the first month of the&#xD;
           study.&#xD;
&#xD;
        2. Recruitment Methods&#xD;
&#xD;
           Patients likely to meet inclusion/exclusion criteria will be recruited from the&#xD;
           inpatient and outpatient units at Beth Israel Medical Center via advertisements in&#xD;
           newspapers and other media, or by physician referral from sites participating in the&#xD;
           registry. Outpatients will also be screened at Beth Israel Medical Center.&#xD;
&#xD;
           Sample Description&#xD;
&#xD;
           Patient recruitment will reflect the referral patterns to the outpatient clinic&#xD;
           participating in the study. Given the gender distribution in the prevalence of bipolar&#xD;
           II disorder, it is expected that approximately half the sample size will be female and&#xD;
           half will be male. It is expected that the sample composition will be approximately 80%&#xD;
           Caucasian, 10% African American, 5% Hispanic, and 5% Asian or other ethnic group.&#xD;
&#xD;
        3. Study Procedures&#xD;
&#xD;
      Screening, Informed Consent&#xD;
&#xD;
      Investigators will screen patients based on the inclusion/exclusion criteria after a written&#xD;
      informed consent, and general medical and psychiatric histories, are obtained. At enrollment,&#xD;
      a general medical history and comprehensive physical and neurological examinations will be&#xD;
      obtained, along with screening laboratory analysis of blood and urine (for medical&#xD;
      exclusions, drug screen, and pregnancy screen if appropriate).&#xD;
&#xD;
      During the baseline period (after informed consent) but prior to treatment with CES&#xD;
      participants' physical functioning, emotional well being, life satisfaction, depression and&#xD;
      manic symptoms will be assessed. And documentation of prior and current mood disorder&#xD;
      treatments; documentation of other regularly-used, prescribed, and over-the-counter&#xD;
      medications and supplements/botanicals; and the neuropsychological battery (described below)&#xD;
      will be obtained.&#xD;
&#xD;
      Patients will be maintained on the same dosage of their antidepressant medication beginning&#xD;
      two weeks prior to entering the study (four weeks for fluoxetine). During phase I (two weeks)&#xD;
      and phase II (two weeks), patients will be asked to keep their medications and dosages&#xD;
      stable. In phase III of the study, medications and dosages may be adjusted as needed.&#xD;
&#xD;
      EEG recording&#xD;
&#xD;
      We will record a standard 64 channel EEG for five minutes before the first CES session and&#xD;
      for five minutes after the first CES session, as well as after the 8th week to evaluate acute&#xD;
      and long term effects of CES on EEG. The electrodes are given 25 minutes to stabilize and a&#xD;
      CES sensation threshold is determined for the patient.&#xD;
&#xD;
      Phase I, Randomization Phase&#xD;
&#xD;
      Patients will be randomized to either the active CES or control group on a 1:1 basis.&#xD;
      Patients will be asked about changes in medical state, medication or caffeine or alcohol&#xD;
      intake, change in sleep patterns prior to beginning study procedures at each visit. CES&#xD;
      sessions will be performed 5 days a week for two weeks.&#xD;
&#xD;
      Sham CES is performed by turning the current on until the patient experiences a tingling&#xD;
      sensation on the scalp, then decreasing the current to just below threshold. This is the sham&#xD;
      procedure described in the literature.&#xD;
&#xD;
      Criteria for Treatment Continuation / Discontinuation (Phase I):&#xD;
&#xD;
      At the end of each week, a blinded rater will administer the Hamilton Depression Rating Scale&#xD;
      (HRSD 17 item), Global Assessment of Functioning (GAF), Clinical Global Impression (CGI). At&#xD;
      the end of Phase 1, patients will be classified into one of three groups:&#xD;
&#xD;
        1. Stable remission: HRSD17 â‰¤ 7 at the end of the second week. These patients go to Phase 3&#xD;
           and enter naturalistic follow up.&#xD;
&#xD;
        2. Non-improving: Less than 30% decrease in the Hamilton Depression rating Scale (HRSD)&#xD;
           from baseline. These patients will be crossed over to the open-label CES in Phase II.&#xD;
&#xD;
        3. Improving: 30% or greater decrease in the HRSD from baseline. These patients will also&#xD;
           be crossed over to receive open label CES in Phase II.&#xD;
&#xD;
      Phase II, Open-Crossover Trial&#xD;
&#xD;
      Phase II is the open label phase in which subjects will receive active CES for two weeks.&#xD;
&#xD;
      Phase III, Naturalistic follow up&#xD;
&#xD;
      2-month naturalistic follow-up for all study participants is included to examine whether&#xD;
      antidepressant effects of CES persist beyond the acute, active treatment phase. Patients will&#xD;
      be maintained on their medications unless changing types and dosages of medication is&#xD;
      clinically indicated.&#xD;
&#xD;
      Patients will be rated weekly, up to 2 months (8 follow up visits). The following assessments&#xD;
      will be performed at the weekly follow-up visits: symptoms of depression and global&#xD;
      assessment of functioning. Neuropsychological Testing will be done at baseline, two weeks,&#xD;
      four weeks and eight weeks.&#xD;
&#xD;
      Drop-out Criteria&#xD;
&#xD;
      If a patient has a CGI Global Improvement score of 6 or higher (i.e. &quot;Much Worse&quot; or &quot;Very&#xD;
      Much Worse&quot; compared to baseline) sustained across 2 assessments they will be withdrawn from&#xD;
      the study and referred to appropriate treatment. Additionally, if a patient develops&#xD;
      psychotic symptoms, develops acute suicidal intent and/or plan, needs psychotropic&#xD;
      medications to be changed or increased to treat clinical worsening, or requires inpatient&#xD;
      psychiatric admission, or develops manic symptoms; they will be withdrawn from the study and&#xD;
      referred to appropriate treatment.&#xD;
&#xD;
      Data Analysis&#xD;
&#xD;
      An n of 20 was selected based on the precedent set by a previous CES study where a 50%&#xD;
      reduction in GAD symptoms was observed with an n of 12 (p =0.01) (Bystritsky, Kerwin, &amp;&#xD;
      Feusner, 2008). We expect similar effect size in our study.&#xD;
&#xD;
      4. Confidentiality&#xD;
&#xD;
      Subjects will not be mentioned by name. Research records, like other medical and clinical&#xD;
      records, will be kept confidential to the extent permitted by law. Any information obtained&#xD;
      during this study will only be available to the research staff, institutional personnel, or&#xD;
      to federal and New York State regulatory personnel. There are legal advocacy organizations&#xD;
      that have the authority under state law to access otherwise confidential research records,&#xD;
      though they cannot re-disclose this information without subject's consent. All information&#xD;
      will be stored in locked files and will not have subject's name or any other identifying&#xD;
      information associated with it.&#xD;
&#xD;
      All data (written and electronic) will be coded. A master list matching the subject with&#xD;
      codes will be kept under lock and key, separate from any research records or the computer&#xD;
      database, with access restricted to research staff, to the extent permitted by law. Only&#xD;
      staff directly involved in this project will have access to the master list linking subject's&#xD;
      name to code numbers. Subject's name and other personal identifying information will be&#xD;
      stored in files and in an electronically secure database at the hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Beck Depression Inventory (BDI) Score at Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>BDI is a validated, self-report measure used to assess the level of depression symptom severity. BDI values range from 0 (normal) to 63 (extreme depression). Mean Change = (Week 2 Mean Score - Baseline Mean Score).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score at Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>Q-LES-Q is a validated 16-item self-report measure of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning such as physical well-being, work, home, social relationships and leisure activities. Each item is rated on a 1 - 5 point scale. Q-LES-Q values range from 0 (very low quality of life) to 100 (high quality of life). Mean Change = (Week 2 Mean Score - Baseline Mean Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Clinical Global Impressions Illness Severity (CGI-S) Score at Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>CGI-S instrument measures the level of severity of illness rated by a qualified clinician. CGI-S values range from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). Mean Change = (Week 2 Mean Score - Baseline Mean Score).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Bi-polar II Disorder</condition>
  <arm_group>
    <arm_group_label>Active CES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham CES</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The CES sham group will receive sham CES (device off)for 20 minutes 5 times per week for two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active CES</intervention_name>
    <description>The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.</description>
    <arm_group_label>Active CES</arm_group_label>
    <other_name>FW-100 Fisher Wallace Stimulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham CES</intervention_name>
    <description>The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.</description>
    <arm_group_label>Sham CES</arm_group_label>
    <other_name>FW-100 Fisher Wallace Stimulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of bipolar II disorder currently in a depressive episode (without psychotic&#xD;
             features)&#xD;
&#xD;
          2. Pretreatment HRSD score of &gt;/= 13 and &lt;28 and a CGI less than or equal to 5.&#xD;
&#xD;
          3. Between 18 and 85 years old&#xD;
&#xD;
          4. Willing to provide informed consent -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a history of bipolar II disorder previously untreated with medication, or&#xD;
             bipolar I disorder, or is in a manic or mixed episode; unipolar depression,&#xD;
             schizophrenia, schizo-affective disorder, other (non mood disorder) psychosis,&#xD;
             depression secondary to a medical condition, mental retardation, substance dependence&#xD;
             or abuse within the past year (except nicotine), psychotic features in this or&#xD;
             previous episodes, amnestic disorder, dementia or MMS (mini mental exam) less than or&#xD;
             equal to 24, delirium. HRSD score &gt; 28 and CGI &gt; 5.&#xD;
&#xD;
          2. Significant current history of autoimmune, endocrine, disorder affecting the brain. No&#xD;
             unstable cardiac disease, uncontrolled hypertension or sleep apnea.&#xD;
&#xD;
          3. Changes in psychotropic medications for 2 weeks prior to study entry amd unable to&#xD;
             maintain stable doses throughout the trial.&#xD;
&#xD;
          4. Subject has active suicide plan, or history of suicide attempt within the past 12&#xD;
             months.&#xD;
&#xD;
          5. Pregnancy or positive serum pregnancy test.&#xD;
&#xD;
          6. Having a pacemaker&#xD;
&#xD;
          7. History of: skull fracture, craniotomy, deep brain stimulation, cochlear implants,&#xD;
             dorsal column pacemaker, cardiac pacemaker, seizures or epilepsy.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Galynker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <results_first_submitted>February 12, 2015</results_first_submitted>
  <results_first_submitted_qc>November 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 24, 2015</results_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active CES</title>
          <description>The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.&#xD;
FW -100 Fisher Wallace Cranial Electrical Stimulator: The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sham CES</title>
          <description>The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.&#xD;
Sham CES via FW-100 Fisher Wallace Stimulator: The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active CES</title>
          <description>The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.&#xD;
FW -100 Fisher Wallace Cranial Electrical Stimulator: The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sham CES</title>
          <description>The CES sham group will receive sham CES (device off)for 20 minutes 5 times per week for two weeks.&#xD;
Sham CES via FW-100 Fisher Wallace Stimulator: The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.57" spread="11.43"/>
                    <measurement group_id="B2" value="43.78" spread="18.26"/>
                    <measurement group_id="B3" value="47.62" spread="15.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score at Week 2</title>
        <description>Q-LES-Q is a validated 16-item self-report measure of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning such as physical well-being, work, home, social relationships and leisure activities. Each item is rated on a 1 - 5 point scale. Q-LES-Q values range from 0 (very low quality of life) to 100 (high quality of life). Mean Change = (Week 2 Mean Score - Baseline Mean Score).</description>
        <time_frame>Baseline to Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Participants received 2 mA CES treatment for one 20 minute session per day, 5 times per week for two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Participants received sham CES (device off) for 20 minutes 5 times per week for two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score at Week 2</title>
          <description>Q-LES-Q is a validated 16-item self-report measure of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning such as physical well-being, work, home, social relationships and leisure activities. Each item is rated on a 1 - 5 point scale. Q-LES-Q values range from 0 (very low quality of life) to 100 (high quality of life). Mean Change = (Week 2 Mean Score - Baseline Mean Score).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.50" spread="18.53"/>
                    <measurement group_id="O2" value="-1.50" spread="15.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Clinical Global Impressions Illness Severity (CGI-S) Score at Week 2</title>
        <description>CGI-S instrument measures the level of severity of illness rated by a qualified clinician. CGI-S values range from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). Mean Change = (Week 2 Mean Score - Baseline Mean Score).</description>
        <time_frame>Baseline to Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Participants received 2 mA CES treatment for one 20 minute session per day, 5 times per week for two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Participants received sham CES (device off) for 20 minutes 5 times per week for two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Clinical Global Impressions Illness Severity (CGI-S) Score at Week 2</title>
          <description>CGI-S instrument measures the level of severity of illness rated by a qualified clinician. CGI-S values range from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). Mean Change = (Week 2 Mean Score - Baseline Mean Score).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.69"/>
                    <measurement group_id="O2" value="-0.11" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Beck Depression Inventory (BDI) Score at Week 2</title>
        <description>BDI is a validated, self-report measure used to assess the level of depression symptom severity. BDI values range from 0 (normal) to 63 (extreme depression). Mean Change = (Week 2 Mean Score - Baseline Mean Score).</description>
        <time_frame>Baseline to Week 2</time_frame>
        <population>Intent to treat population (all participants who received at least one dose of intervention). Last observation carried forward (LOCF) imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Participants received 2 mA CES treatment for one 20 minute session per day, 5 times per week for two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Participants received sham CES (device off) for 20 minutes 5 times per week for two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Beck Depression Inventory (BDI) Score at Week 2</title>
          <description>BDI is a validated, self-report measure used to assess the level of depression symptom severity. BDI values range from 0 (normal) to 63 (extreme depression). Mean Change = (Week 2 Mean Score - Baseline Mean Score).</description>
          <population>Intent to treat population (all participants who received at least one dose of intervention). Last observation carried forward (LOCF) imputation method.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.01" spread="6.95"/>
                    <measurement group_id="O2" value="-3.76" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Four weeks for active treatment and two weeks for sham treatment</time_frame>
      <desc>Safety population included all participants who received at least one doze of intervention. Assessments were made before and after each intervention using a side-effects questionnaire.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>Participants received 2 mA CES treatment for one 20 minute session per day, 5 times per week for four weeks.</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>Participants received sham CES (device off) for 20 minutes 5 times per week for two weeks (placebo period), and after cross-over into open-label phase participants received 2 mA CES treatment for one 20 minute session per day, 5 times per week for another two weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A small sample size.&#xD;
A possible self-selection bias due to extensive time commitment required from the study participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Igor Galynker MD PhD</name_or_title>
      <organization>Mount Sinai Beth Israel</organization>
      <phone>212-420-4535</phone>
      <email>igalynke@chpnet.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

